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 The endothelial layer of blood vessels is able to produce a number of vasoactive 
substances, and these substances can work to either relax or contract the underlying 
vascular smooth muscle. A hallmark of hypertension is the development of endothelial 
dysfunction, a shift in the balance of these substances to a state of increased contraction. 
Hydrogen sulfide (H2S) has recently garnered much interest as a gaseous signaling 
molecule with the discoveries that is can relax isolated blood vessels and lower blood 
pressure in young spontaneously hypertensive rats (SHR). Here we investigate whether 
chronic H2S treatment (56 µmol/kg of the H2S donor sodium hydrosulfide (NaHS), once 
daily for 5 weeks) can lower the blood pressure of adult aged SHR when compared to 
normotensive control Wistar Kyoto rats (WKY), and whether there are changes in the 
endothelium-dependent relaxation and contraction pathways. Invasive hemodynamic 
measurements including systolic, diastolic, and mean blood pressure, as well as heart rate 
were measured. Isolated vessel myography was performed on the common carotid artery 
to determine whether there were changes in the endothelium-dependent and independent 
relaxation and contraction pathways. This was achieved using a number of dose response 
curves. Changes in endothelium dependent dilation to ACh, VSM sensitivity to NO and 
H2S, and NO bioavailability were tested with dose response curves using ACh, SNP (an 
NO donor), H2S and indomethacin, respectively. TP receptor sensitivity, as well as COX-
mediated constriction in quiescent vessels was also examined by using the TP receptor 
agonist U46619 and L-NAME (eNOS inhibitor), respectively. Biochemical analyses 
included Western blotting to assess protein levels of CSE (H2S generating enzyme) and 
eNOS (NO generating enzyme) as well as determining prostacyclin production. 
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Determination of H2S concentration in the blood via a sulfide electrode was also 
performed to confirm that the H2S treatment was effective. There were no main effects of 
H2S treatment in any of the hemodynamic measurements taken. ACh dose response 
revealed a blunting in the recontraction at 10-5 and 10-4.5 log M concentrations (p<0.05) in 
SHR treated with H2S. No effects were observed, however, in any other myography 
protocol. Western blot analysis revealed no difference in the protein expression of CSE or 
eNOS with H2S treatment, and there were no differences in prostacyclin production with 
H2S treatment. In conclusion, these data suggest that H2S may not be an effective 
treatment for hypertension in adult SHR, in contrast to previous work finding a similar 
dosing regimen to be effective at lowering blood pressure in young SHR. Further work 
must be completed to ascertain the mechanism for the alteration in the ACh dose 
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 The endothelium is a single layer of cells that lines the luminal surface of blood 
vessels. Prior to 1980, this layer was thought to be a barrier between the circulating blood 
and the vascular smooth muscle (VSM) and nothing more. Then in 1980, the seminal 
work by Furchgott and Zawadzki led to the realization that the endothelium was able to 
synthesize and release a factor that caused relaxation of the underlying smooth muscle 1. 
This factor was termed an endothelium-dependent relaxing factor (EDRF), and was later 
identified as nitric oxide (NO) 2. The realization that the endothelium was able to produce 
EDRFs led to a paradigm shift in vascular research, to a focus on what role the 
endothelium played in the maintenance of vascular tone. 
 It is now well established that along with EDRFs, the endothelium is also able to 
synthesize and release a number of endothelium-dependent contracting factors (EDCF) 
and endothelium-dependent hyperpolarizing factors (EDHF) that also act on the VSM to 
cause contraction and relaxation, respectively. It is the balance and interplay between 
these three groups of factors that plays a large part in the endothelial control of vascular 
tone. Two of the most important EDRFs are the previously mentioned NO, and 
prostacyclin (PGI2). In a normotensive state, these two molecules work to relax the 
overlying smooth muscle in response to certain mechanical or pharmacological stimuli. 
In diseased states however, such as hypertension, a balance shift occurs which leads to 
underactive EDRF pathways and overactive EDCF pathways 3. Endothelial dysfunction 
that results from this shift is recognized as a hallmark of vascular disease, and a major 
predictor of future cardiovascular complications.  
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 Along with NO, more gasotransmitters have been identified as being important 
signaling molecules, including carbon monoxide and hydrogen sulfide (H2S). H2S has 
garnered much attention in the last ten years, with more and more evidence being 
presented suggesting that apart from being a highly toxic gas with an offensive odour, at 
lower concentrations it is actually a signaling molecule important to the maintenance of 
vascular tone 4. 
In the following sections, the role of NO and PGI2 in the regulation of vascular 
tone will be outlined in detail, including how that role changes in endothelial dysfunction. 
Further detail will also be given on EDHF relaxation and the role of reactive oxygen 
species (ROS). Finally, H2S biology will be examined, with emphasis on its role as a 
vasodilator and its potential importance in the progression and possible treatment of 
hypertension. 
 
Nitric Oxide Signaling: 
 Nitric oxide is a gaseous signaling molecule that is able to diffuse from the 
endothelial cell to the VSM and cause relaxation. NO is produced by any of the three 
nitric oxide synthase (NOS) isoforms: neuronal NOS (nNOS), inducible NOS(iNOS), and 
endothelial NOS (eNOS). As the name suggests, most NO produced in the endothelium 
comes from eNOS, which can be activated by a Ca2+-dependent pathway. In response to 
external stimuli (cell-surface receptor activation, shear stress), intracellular Ca2+ 
concentrations ([Ca2+]i) increase in the endothelium which in turn leads to Ca2+ binding 
to calmodulin to form a Ca2+-calmodulin complex. This complex then binds to eNOS, 
leading to its activation and the production of NO. Once activated, eNOS utilizes the 
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amino acid L-arginine and oxygen as substrates to synthesize NO, which then diffuses to 
the VSM. The main physiological target of NO is soluble guanylyl cyclase (sGC), which 
converts GTP to cGMP, leading to activation of protein kinase G (PKG) and a 
subsequent decrease in [Ca2+]i. The lower levels of Ca2+ in the VSM lead to decreased 
formation of calcium-calmodulin complex, leading to decreased cross-bridge formation 
and smooth muscle relaxation 5 (Figure 1). 
 In diseases associated with endothelial dysfunction, such as hypertension, major 
differences in NO signaling are observed that lead to deficits in smooth muscle 
relaxation. NO bioavailability is markedly reduced with endothelial dysfunction, in part 
due to increased ROS 3. The following discussion on ROS pertains only to its 
involvement in NO interaction and scavenging. A detailed section outlining the more 
diverse role of ROS in the endothelium and ROS-H2S interactions will be discussed later. 
Increases in ROS, such as superoxide anion, react with the unstable NO molecule to 
create peroxynitrite. Peroxynitrite in itself is a dangerous and destructive molecule and 
can cause damage to surrounding protein structures. More importantly however, the 
formation of peroxynitrite decreases the amount of NO that is able to relax the VSM, 
effectively reducing NO bioavailability. Experimental models that introduce exogenous 
superoxide or inhibit superoxide dismutase (SOD) show decreased NO bioavailability. In 
contrast, treating vessels with SOD mimetics or inhibiting the pro-oxidant enzyme 






 Prostacyclin (PGI2) is important both in EDRF signaling as well as in the 
progression to endothelial dysfunction. Upon flow stimulus or cell surface receptor 
stimulation, resultant increases in endothelial [Ca2+]i cause Ca2+-dependent phospholipase 
A2 (PLA2) activation. This leads to the release of arachidonic acid (AA) from the cell 
membrane, which can be metabolized by a number of enzyme systems, most notably by 
cyclooxygenase-1 and 2 (COX-1, 2), into endoperoxides 9. The endoperoxides are then 
synthesized into a number of bioactive prostaglandins through their respective synthases 
10. Of these prostaglandins, PGI2 is one of the most abundantly produced, and it is 
released by the endothelium to diffuse to the VSM. PGI2 interacts with the prostacyclin 
receptor (IP) on the surface of the VSM. This receptor in turn undergoes a 
conformational change and stimulates adenylate cyclase (AC) through a G-protein 
coupled response. AC then converts ATP to cAMP, which causes activation of protein 
kinase A (PKA) leading to a decrease in [Ca2+]i and relaxation (Figure 2). 
 While a normotensive vessel demonstrates relaxation with stimulation of the PGI2 
pathway, a very different scenario is observed during endothelial dysfunction. In 1986, 
Luscher et al. 9 noted that in the aorta of spontaneously hypertensive rats (SHR), higher 
concentrations of acetylcholine (ACh) cause a re-constriction of the vessel while a 
blunting of the relaxation response was observed at low concentrations of ACh, an effect 
not seen in the Wistar-Kyoto (WKY) controls. A corroboratory result was also observed 
in quiescent rings from WKY and SHR animals, where rings without endothelium from 
both strains and with endothelium from the WKY showed no development in tension in 
response to the addition of ACh, but the SHR rings with endothelium began developing 
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tension at higher ACh concentrations. Upon further investigation with a number of 
inhibitors, these investigators concluded that the metabolite causing contraction was a 
product of AA metabolism through the COX pathway. Further research has shown that 
the metabolite responsible for the EDCF response in hypertension is PGI2 11 (Figure 2). 
 The transition to endothelial dysfunction in hypertension involves many changes 
to the COX mediated PGI2 production pathway. The first major change involves the 
expression levels of COX enzymes in the endothelium. As mentioned previously, the 
COX enzyme exists in two isoforms, COX-1 and COX-2. COX-1 is constitutively 
expressed in most cells with a 20-fold higher expression in endothelial cells than in VSM 
3. COX-2 has a much lower expression level in both tissues, but this can be increased at 
sites of inflammation. SHR animals show a much higher expression of COX-1 than 
WKY controls 12, as well as increased expression of certain prostanoid synthases, in 
particular prostacyclin synthase 13. This suggests that higher prostanoid production as 
well as increased prostanoid conversion to PGI2 could play a major role in the greater 
EDCF response seen in hypertension 12. 
 Each of the prostanoids released by COX preferentially stimulates a specific VSM 
surface receptor. In the case of PGI2 this receptor is the IP receptor, which leads to 
smooth muscle relaxation. Thromboxane A2 is another prostanoid released by COX that 
stimulates the thromboxane-prostanoid (TP) receptor, which causes smooth muscle 
contraction by opening receptor-mediated and voltage gated Ca2+ channels, leading to 
increased [Ca2+]i 14. In SHR animals, PGI2 loses its ability to cause relaxation. Due to a 
dysfunction in the IP receptor, the overflow of PGI2 begins to cause contraction by 
stimulating the TP receptor 15,16. Interestingly, the protein and mRNA expression of TP 
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receptors is not different between SHR and WKY animals 17, yet the SHR vessels do 
seem to become hyper-responsive to certain protstanoids such as PGH2 18. Downstream 
signaling cascades that are activated by TP receptor stimulation might also be altered in 
hypertension. This could be attributed to Rho-ROCK activation in the VSM, which could 
lead to enhanced EDCF actions in the VSM 19. Increased COX-1 expression and PGI2 
production, IP receptor dysfunction, TP receptor hypersensitivity and enhancements to 
downstream signaling cascades all play a role in overactive EDCF activation. 
 Changes in both the bioavailability of NO and the actions of PGI2 are important 
steps in the progression of endothelial dysfunction. More and more literature is being 
produced that supports the idea that the changes in both of these pathways are related to 
an increased level of oxidative stress, as apparent from an increased production of ROS 
and a decreased ability to scavenge excess (Figure 3).  
 
Reactive Oxygen Species: 
 In a normotensive state, physiological levels of ROS can aid in normal cell 
homeostasis, with several antioxidant mechanisms in place to ensure excess ROS is 
quenched to ensure proper cell function. During endothelial dysfunction, however, 
pathological level of ROS begin to accumulate, leading not only to impairments in proper 
cell signaling pathways and cell function, but also to impairments in the ability for ROS 
scavenging by antioxidant mechanisms 20. 
 Unchecked ROS production can be detrimental to relaxation signaling pathways.  
ROS is produced at many different locations in both the endothelium and the VSM, 
mainly: NADPH oxidase, xanthine oxidase, COX-1 and 2 as well as uncoupled eNOS 21. 
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The most common ROS are superoxide, hydrogen peroxide and peroxynitrite 3,5. A 
significant amount of superoxide in the vasculature is produced in the endothelium, as 
considerable decreases in superoxide production can be seen in SHR and WKY vessels 
that have had the endothelium removed 22. NADPH oxidase protein expression, as well as 
activity, is increased in hypertension leading to increased production of superoxide 23. 
Superoxide can inhibit sGC, decreasing the effect that any still available NO has on VSM 
relaxation 24 -26 as well as inactivating Ca2+-activated potassium channels 27. As mentioned 
previously, superoxide can combine with NO to form the potent oxidant peroxynitrite, 
decreasing NO bioavailability. Peroxynitrite can act to inhibit guanylyl cyclase, reducing 
the effectiveness of NO signaling as well as inhibiting superoxide dismutase, and this 
leads to further increases in superoxide 26,28. Peroxynitrite can also work to uncouple 
eNOS by oxidizing complexes within the enzyme and by reducing co-factor availability. 
Production of NO is then compromised and superoxide is produced instead (Figure 3).  
 
Hydrogen Sulfide: 
 Hydrogen sulfide (H2S), best known for its offensive “rotten egg” odor, has been 
known to be a very toxic gas for almost 300 years 29. As a broad-spectrum poison, all 
body systems are affected with overexposure, with the central nervous system and the 
pulmonary system being most affected. H2S toxicity involves inhibition of the 
mitochondrial cytochrome oxidase and the major lethal consequence is loss of central 
respiratory drive, by way of respiratory center brainstem lesions 30. Experiments in the 
late 1800s and early 1900s have shown that many bacteria have the ability to synthesize 
and produce H2S, but in the late 1980s endogenous levels of H2S were found in the rat 
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brain 31. In 1996, Abe and Kimura 32 published a seminal paper that described H2S 
production in rat hippocampus by an enzyme-regulated pathway with the ability to 
influence long-term potentiation in the brain. Since then, H2S has garnered much interest 
as an important gasotransmitter with sites of action all over the body. In 2002, Zhao et al. 
presented work that H2S had the ability to relax blood vessels in a dose dependent 
manner 4. Then in 2008, Yang et al. demonstrated that genetic knockout mice missing the 
enzyme to synthesize H2S demonstrated advanced hypertension. Some known 
cardiovascular actions of H2S will be examined in more detail, as this thesis examines 
cardiovascular responses to exogenous H2S. 
 H2S is produced endogenously by two pyroxidal-5’-phosphate-dependent 
enzymes. Cystathionine-β-synthase (CBS) is found primarily in brain tissue, with little 
expression in the vasculature 4,32. The opposite holds true for cystathionine-γ-lyase (CSE), 
as it is the main H2S synthase in the vasculature, with little evidence that it is found in the 
central nervous system 32. CSE and CBS both use the substrate ι-cysteine to synthesize 
H2S. CSE activation and production of H2S seems to be triggered in a manner very 
similar to that of NO. Upon endothelial stimulation by methacholine (1µM for ten 
minutes, a muscarinic cholinergic receptor stimulant), H2S levels in cultured endothelial 
cells tripled compared to being incubated with vehicle only. Production of H2S also 
seems to be calcium-calmodulin dependent, as the addition of the calcium ionophore 
A23187 significantly increased H2S production, whereas the presence of the calmodulin 
antagonist W7 abolished the increased H2S production 33. 
 H2S has been proposed as the newest member of the gasotransmitter family, 
which includes NO and carbon monoxide 34,35. H2S, however, seems to work more as an 
 9 
EDHF than an EDRF. Being a small gaseous molecule, H2S can readily pass through 
membrane barriers to access specific sites of action. H2S has been shown to directly act 
upon KATP channels on the VSM due to the fact that it can sulfhydrate KATP channel 
subunits, and its relaxation effect is mimicked by pinacidil (a KATP channel opener) and 
abolished by glibenclamide (a KATP channel blocker) 36. Opening of these KATP channels 
causes smooth muscle hyperpolarization with an end result of VSM relaxation (Figure 4). 
H2S has been shown to relax a number of different artery types, from isolated rat aorta 37 
to mesenteric arteries 38. Contributing to the idea that H2S could be an important 
vasodilator, CSE knockout mice have been shown to demonstrate pronounced 
hypertension 33, and animals with L-NAME-induced hypertension 39, high blood flow-
induced pulmonary hypertension 40, and hypoxic pulmonary hypertension 41 all have 
decreased CSE mRNA expression and H2S production. H2S could also play a part in the 
treatment of hypertension. Interestingly, young hypertensive animals (4 weeks old) that 
are treated chronically with sodium hydrosulfide (NaHS, a H2S donor) injections show a 
decrease in blood pressure, as well as increases in CSE mRNA expression and H2S 
production 42,43. This indicates that H2S could be very important in the maintenance of 
blood pressure and the progression of hypertension.  
 H2S and NO seem to have a very complicated relationship. There are many 
studies that show conflicting, and oftentimes opposite, effects that one molecule has on 
the other. This is most notably seen with their functional interactions. In rat aorta, the 
actions of SNP were shown to be decreased in the presence of 60µM NaHS 37. It was 
hypothesized that this reduction in efficacy could be due to a newly formed S-
nitrosothiol, which in the short term would decrease NO bioavailability and lead to a 
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decrease in SNP effect, but could also act as a NO buffer for which could later release 
NO for future effect. In stark contrast to this, Hosoki et al. found that the addition of 
30µM NaHS had additive effects to SNP dilation 44. It is difficult to determine which 
effect represents true physiological actions, as the studies used different animal strains 
(Sprague Dawley and WKY, respectively), precontraction drugs (phenylephrine and 
norepinephrine, respectively) and tissue preparations (aortic rings and helical strips, 
respectively). In the end, it is likely that there are functional interactions of H2S and NO 
that are complex, resulting in a combined action not simply being a summation of their 
individual effects. 
 NO seems to have a positive effect on H2S production. Incubation of cultured 
vascular smooth muscle cells with SNAP results in an increase in the transcriptional 
levels of CSE, possibly allowing for increased H2S production 36,45. Incubation of 
homogenized vascular tissue with SNP also increases the accumulation of H2S 37.  In 
animals treated with the NOS inhibitor L-NAME, CSE activity and expression were 
significantly reduced, leading to reductions in H2S production 39. There is no evidence as 
of yet to show that NO can directly interact with CSE and alter its activity.  
 While the effects of NO of H2S production seem to be mostly positive, the effects 
that H2S has on NO production do not seem to be straightforward. Treatment with NaHS 
has been shown to decrease NO formation, activity of eNOS and to decrease ι-arginine 
transport 46. Treatment with H2S can also work to directly inhibit all three of the NOS 
isoforms 47,48. Interestingly, recent evidence shows that H2S might actually increase NO 
production and increase eNOS activity. Meng et al. showed that in the rat corpus 
cavernosum, treatment with NaHS increases the expression of both eNOS mRNA and 
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eNOS protein content. This increase in protein also led to an increased production of NO 
49. Evidence has also been presented that H2S can stimulate an increase in [Ca2+]i by 
opening intracellular Ca2+ channels 50. The opening of these channels and subsequent 
increase in [Ca2+]i then causes an increase in calcium/calmodulin complex formation, 
leading to direct activation of eNOS. This also leads to the activation of 
calcium/calmodulin-dependent protein kinase (CaMKII) which can activate eNOS on 
Ser1177, leading to increased NO production 50. This rise in [Ca2+]i has been shown to be 
from mainly intracellular stores, and not due to decreased extrusion of Ca2+ by inhibition 
of the sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA) 51. 
 There also seems to be evidence supporting H2S as an antioxidant. H2S is a 
powerful reducing agent and has been shown to interact with many different ROS, as 
well as antioxidant systems. Exogenous administration of H2S has been shown to directly 
scavenge superoxide as well as hydrogen peroxide in rat models of myocardial injury 52,53. 
H2S inhibits superoxide formation in cultured vascular smooth muscle cells that have 
been treated with the TP receptor agonist U46619 54. Exogenous H2S can also inhibit and 
decrease expression of NADPH oxidase, leading to decreased superoxide formation 54,55. 
Peroxynitrite is another molecule that can react with H2S. H2S has been shown to 
significantly reduce the amount of peroxynitrite-mediated tyrosine nitration to a similar 
extent as reduced glutathione, an antioxidant known to be a powerful scavenger of 
peroxynitrite 56. In relation to antioxidant systems, H2S can induce glutathione synthesis 
and reduce oxidized glutathione 57,58. Experimental depletion of glutathione in glioma 
cells can also increase the expression of CSE protein 59. These data suggest that H2S may 
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play an important role as an antioxidant, and that the blood pressure lowering effects it 
has may be due to scavenging of ROS and increasing NO bioavailability. 
 
Purpose: 
 The following study aims to elucidate the effects of chronic sodium hydrosulfide 
on endothelium-dependent vasomotor function of the CCA. The CCA is an ideal vessel 
for these experiments due to its superficial location, lack of side branches and important 
role in controlling brain blood flow. Vasomotor functions will be investigated, for the 
first time, in both the adult SHR and WKY animal models. Changes in associated 
biochemical parameters and in hemodynamic measures will also be examined. 
Specifically, the following will be examined: 
1. Whether there is a blood pressure lowering effect of chronic H2S in adult SHR 
animals with established hypertension. 
2. Effects of chronic H2S on endothelium-dependent relaxation. This will include 
possible changes in endothelium dependent dilation to ACh, VSM sensitivity to 
NO and H2S, and NO bioavailability. 
3. Effects of chronic H2S on endothelium-dependent contractions. This will include 
examining TP receptor sensitivity as well as COX-mediated constriction in 
quiescent vessels. 
4. Effects of chronic H2S on the expression of a number of important proteins 
including eNOS and CSE. We will also be examining the possible differences in 




1. Chronic H2S treatment will improve endothelium-dependent and possibly 
endothelium-independent relaxations in the CCA of SHR animals but not in 
WKY. This will be observed as decreased re-constriction to higher concentrations 
of ACh, and increased relaxation in vessels incubated with indomethacin.  
2. Chronic H2S treatment will decrease the endothelium-dependent contractions in 
SHR animals. This will be observed as a decrease in the ACh stimulated tension 
seen in quiescent SHR vessels incubated with L-NAME, and less tension 
development with U46619 stimulation. 
3. Chronic H2S treatment will decrease blood pressure in adult SHR animals, but 
have no effect on WKY animals. This will be observed as a decrease in systolic, 
diastolic and mean arterial blood pressure. 
4. Chronic H2S treatment will result in decreased PGI2 production in SHR but not in 














Figure 1: Activation of the muscarinic receptor by ACh causes an increase in 
intracellular calcium concentrations, leading to the activation of eNOS and the 
conversion of L-Arginine to NO (1). NO then diffuses to the VSM where it activates 
soluble guanylyl cyclase (sGC), converting GTP to cGMP (2). cGMP then activates PKG 
(3), leading to relaxation of the VSM via decreased formation of Ca2+-CaM and less 











Figure 2: Activation of the muscarinic receptor by ACh causes an increase in 
intracellular calcium concentrations, activating PLA2 which releases acachadonic acid 
from the cell membrane (1). Arachadonic acid is then converted to PGH2 by COX-1, with 
PGH2 being converted to PGI2 by PGIS (2). PGI2 then activates the IP receptor on the 
VSM, which activates AC via a G-protein coupled response (3). AC then converts ATP to 










Figure 3: The hallmark of hypertension is the progression of endothelial dysfunction. 
Increases in ROS production and decreases in ROS scavenging create a pro-oxidative 
environment in the endothelial cell. This ROS can react with eNOS, uncoupling it and 
causing it to produce less NO and instead produce superoxide (1). Superoxide can also 
react with NO to create the potent oxidant peroxynitrite, leading to decreased NO 
bioavailability and causing more oxidative damage (2). Increased ROS increases the 
expression of COX-1, leading to increased production of PGI2 (3). PGI2 loses its affinity 
for the IP receptor and instead stimulates the TP receptor, causing contraction instead of 










Figure 4: Activation of the muscarinic receptor by ACh causes an increase in 
intracellular calcium concentration which activates CSE in a calcium-calmodulin 
dependent manner (1). CSE then converts L-cysteine to H2S (2), which crosses over to the 














               
Figure 5: EDRF protocol (top tracing): After vessel viability has been tested with 
exposure to 60 mM KCL, vessels are washed with buffer and precontracted with 10-6 log 
M PE. ACh is then administered at increasing concentrations to assess endothelium-
dependent dilation.  
EDCF protocol (bottom tracing): After vessel viability has been tested with exposure to 
60 mM KCL, vessels are washed with buffer and incubated with the drug of choice for 30 












 Male Spontaneously Hypertensive rats (SHR, n=40) and male Wistar Kyoto rats 
(WKY, n=37) were obtained from the University of Waterloo breeding colony. Animals 
were group-housed in a temperature and humidity controlled environment and acclimated 
to a 12-hour reverse light cycle. Animals had free access to standard chow (Harlan) and 
tap water ad libitum. All procedures involving rats were approved by the University of 
Waterloo Animal Care Committee and were in accordance with the guidelines of the 
Canadian Council on Animal Care. 
  
Sodium Hydrosulfide Treatment: 
 Recent studies have shown that 56μmol/kg of sodium hydrosulfide (NaHS) over 5 
weeks results in a significant decrease in blood pressure in young (4 weeks old) SHR 
animals 42. Other studies show that an increased or decreased dose over a longer period of 
time causes no additional blood pressure decreases in the animals 43. Therefore the above-
mentioned dose is appropriate for the current experiments. At 14-17 weeks of age, 
animals were weighed and the 5-week, daily subcutaneous injection protocol began. A 
stock of solution of 1mol/L NaHS was made fresh daily in sterile saline solution. 560 μL 
of this stock was added to 9.44 ml of sterile saline to make a 56 mmol/L injection 
solution. Injecting 0.42cc of this solution into a 420g animal yielded a final dose of 
56μmol/kg. Dose was adjusted as accurately as possible based on weight. SHR and WKY 
animals were randomly split into control and H2S treatment groups, with the control 
groups receiving weight-adjusted subcutaneous injections of saline solution and the H2S 
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treatment group receiving the NaHS injection solution. Hemodynamic measures and 
vasomotor assessments were performed approximately 15 hours after their final dose. 
 
Hemodynamic Measures: 
 A subset of animals (SHR; n=13, WKY; n=15) was used for direct hemodynamic 
measures via the left common carotid artery. Animals were injected with sodium 
pentobarbital (50-65 mg/kg i.p.; Bimeda-MYC, Cambridge, ON) and the level of 
anesthetization was monitored through the withdrawl reflex from a toe pinch. To ensure 
proper levels of anesthetization, additional sodium pentobarbital was injected until 
withdrawl reflex was absent. Animals were placed supine on a heating pad at 38°C 
(Gaymar TP-500, Orchard Park, New York and Temp-Pad; Seabrook Medical Systems). 
Following a small incision into the neck, blunt dissection was used to isolate the left 
common carotid artery. The artery was cleaned with saline and a small incision was made 
at the cephalic end. The calibrated Mikro-Tip pressure catheter (Model SPR-320, 2F 
Mikro-Tip Pressure Transducer Catheter, Millar Instruments, INC., Houston, TX) was 
then inserted into the artery and secured with silk suture (4-0 silk, Look, Reading, PA). A 
stable systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial 
pressure (MAP), and heart rate (HR) were measured for 5-7 minutes. Following 
hemodynamic measures, animals were sacrificed via exsanguination. 
 
Vasomotor Assessment: 
 A different subset of animals (SHR; n=27, WKY; n=22) was used for vasomotor 
assessment experiments. Following anesthetization with sodium pentobarbital, animals 
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were sacrificed by exsanguination. Both common carotid arteries were excised and 
placed in 4° C Krebs-Henseleit buffer (concentration (mmol/L): 131.5 NaCl, 5.0 KCl, 2.5 
CaCl2, 1.2 NaH2PO4, 1.2 MgCl2, 0.023 EDTA, 13.5 NaHCO, and 11.2 glucose). The 
arteries were cut into 2 mm rings with a surgical blade under a dissecting microscope 
(Zeiss; VWR, Mississauga, ON) and then mounted on a wire myograph system (vascular 
myography unit, Radnoti Glass Technology Inc., Monrovia, CA). The arterial rings were 
suspended between a fixed titanium wire attached a glass foot and a titanium triangle 
attached to a force transducer (Model MLT0201/D, ADInstruments). Mounted arterial 
segments were then immered in tissue baths warmed to 38° C and filled with 5 mL 
oxygenated (95%O2/5%CO2) Krebs buffer. 
Previous work in our lab 19 has established the optimal basal length of the CCA to 
be at 2.85g of tension. To achieve this we increase the tension to 2.85g for ten minutes 
followed by a wash with new buffer. This is then repeated two more times until the vessel 
holds steadily at 2.85g. Tension viability was then tested by the addition of 60mM KCL 
to elicit a contraction for 30 minutes followed by three 5-minutes washouts with buffer in 
preparation for the vasomotor experiments.  
 
Myography Experimental Protocols: 
I) ACh, SNP and H2S Dilation Dose-Response Curves 
Phenylephrine (PE) (10-6 mol/L) was used to pre-contract vessel segments until a 
stable plateau was reached. To assess vasorelaxation function of the CCA, an ACh dose-
response curve (10-9-10-4 mol/L and half-concentrations) was constructed to determine 
endothelium-dependent relaxation, and an SNP dose-response curve (10-10-10-4 mol/L 
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and half-concentrations) was constructed to determine endothelium-independent 
relaxation. Indomethacin (INDO, 10-5 mol/L), a COX-1 and 2 inhibitor, was used for one 
preparation to eliminate the endothelium-dependent contraction component and allowing 
for the assessment of NO-bioavailability as established in our previous experiments. 
Vessels were incubated with INDO for 30 minutes prior to PE pre-contraction 19. A H2S 
(10-5-10-3 and half-concentrations) dose-response curve was also constructed to determine 
if there were differences in vascular smooth muscle sensitivity to H2S across treatment 
groups. 
II) ACh and U46619 Constriction Dose-Response Curves 
 Quiescent vessel segments (non pre-constricted) were used for the examination of 
EDCF responses. The eNOS inhibitor L-NAME was added and allowed to incubate for 
30 minutes. At the end of incubation an ACh dose-response curve was constructed to 
assess COX-mediated constriction. A dose-response curve was also constructed using the 
TP receptor agonist U46619 (10-9-10-6 and half-concentrations) to assess possible 
changes in VSM TP receptor sensitivity.  
 
Biochemical Analysis: 
6 keto PGF1α Competitive Enzyme Immunoassay – Prostacyclin Production: 
 Following the peak contraction (highest concentration) in the ACh dose-response 
curve incubated with L-NAME, buffer from the tissue bath was collected and 
immediately frozen in liquid nitrogen and stored at -80° C. The concentration of 6-keto-
PGF1α (stable metabolite of PGI2) in the buffer was assessed using a competitive EIA kit 
(Cayman Chemical), as an index of the PGI2 production by the vessel segments 19. 
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Western Blotting: 
 Two vessel segments not used in the vasomotor assessment experiments were 
frozen in liquid nitrogen and stored at -80°C. Vessel segments were hand homogenized 
with a glass homogenizer (Kontes-Glass, Vineland, NJ) in 150 µL of ice-cold extraction 
buffer (10mM NaH2PO4, 1% SDS, 6M urea at pH7.4). Homogenates were then incubated 
at 60°C for 3 hours with intermittent vortexing, centrifuged (12 min, 12000rpm) and 
supernatant removed and stored at -80°C. Protein concentrations were then assessed 
using the BCA protein assay method. Samples were combined with the BCA working 
reagent (50 parts bicinchoninic acid + 1 part Copper II sulfate) and compared to a bovine 
albumin protein standard curve using spectrometry (OD 527nm, SpectraMax plus 384, 
Molecular Devices, Sunnyvale, CA). Samples were prepared for Western blotting by 
diluting to 1µg/µl.  
 Samples underwent electrophoresis (30µg/lane at 120V for 60-80mins), after 5 
minutes of denaturing at 95°C, in sodium dodecyl sulphate-polyacrylamide gels (SDS-
PAGE) ranging from 7.5% to 12% depending on the molecular weight of the protein of 
interest. Proteins were then transferred onto PVDF membranes (25V for 40 min). 
Immunodetection began by blocking membranes with 5% bovine serum albumin (BSA) 
for 1 hour followed by incubation with protein specific antibodies (eNOS 1:750, CSE 
1:500). Following primary antibody incubation, membranes were incubated with 
secondary antibody made up in either horseradish peroxidase-conjugated anti-mouse or 
anti-rabbit. Membranes were then washed with enhanced horseradish peroxidase/luminol 
chemiluminescence reagents (Amersham, Little Chalfront, UK) and detected using a 
syngene system (Syngene, Cambridge, UK) 19. 
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Statistical Analysis: 
For vasomotor assessment experiments, tension values in the contraction curves 
were expressed as a percentage of KCL pre-contraction. Relaxation curves were 
expressed as a percentage of relaxation from the PE pre-contraction. Dose-response 
curves were analyzed using point-by-point analysis, where strain and treatment 
differences were compared using a student-t test between individual points for a given 
concentration. Strain and treatment differences for maximal response to the highest drug 
concentration and area under the curve were analyzed using 2 way ANOVA. Western 
blots were analyzed using student-t test (α=0.05). Hemodynamic measures and PGI2 
















Animal Characteristics and Hemodynamics: 
 There was no significant difference in final body weight between SHR and WKY 
animals, as well as no difference seen between treatment groups (Table 1). As previously 
reported, SHR animals displayed significantly increased heart rate, mean arterial 
pressure, systolic blood pressure and diastolic blood pressure when compared to the 
WKY controls (P<0.0001). There were no main effects of H2S treatment on any of the 
above parameters. SHR CON and SHR H2S treated animals had a significantly higher 
LV/BW ratio (index of hypertension induced cardiac hypertrophy) when compared to 





There was found to be a very small but significant change in the force produced 
from a 30 min 60mM KCL exposure when comparing all SHR vs. all WKY (Table 2) 
There were no differences when comparing H2S treatment groups to their respective 
control groups (Table 2). 
 
Phenylephrine Pre-Contraction 
Neither strain nor H2S treatment had a main effect on tension development to 10-6 




The results for each vasomotor function test are presented in two subsections: 
SHR and WKY control groups will be examined to present strain differences; followed 
by within strain comparisons to examine differences between control groups and chronic 
hydrogen sulfide treatment. 
 
Endothelium-Dependent Vasorelaxations-ACh 
Comparison of SHR and WKY control 
Point-by-point analysis revealed that WKY displayed much greater relaxation to 
concentrations of 10-6 to 10-4 log M than SHR (Figure 6). WKY demonstrated greater 
relaxation to a maximal dose (MR) of ACh (p<0.0001)(Table 3) as well as a greater area 
under the curve (AUC)( p<0.05)(Table 3). 
Comparison within strain 
Point-by-point analysis revealed significant differences in the SHR H2S treatment 
group compared to SHR controls at the 10-5 and 10-4.5 log M concentrations 
(p<0.05)(Figure 7). There were, however, no statistically significant H2S treatment 
differences with respect to maximal relaxation or AUC (Table 3). 
 
Endothelium-Independent Vasorelaxations-SNP 
Comparison of SHR and WKY control 
Point-by point analysis revealed that WKY displayed a slightly greater relaxation 
to SNP at the 10-10 log M concentration than SHR (WKY: -0.7±1%, SHR: 3±1%, 
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p=0.044)(Figure 8). There were no differences (p=0.2, p=0.6 respectively) between SHR 
and WKY with respect to AUC and maximal relaxation (Table 3). 
Comparison within strain 
No H2S treatment differences were observed in SNP relaxation curves with point-
by-point analysis in either SHR or WKY treatment groups (Figure 8). There were also no 
H2S treatment differences in maximal relaxation or AUC observed (Table 3). 
 
Hydrogen Sulfide Mediated Vasorelaxations 
Comparison of SHR and WKY control 
No differences were observed with the point-by-point analysis (Figure 9). A strain 
difference was observed, with WKY having a greater AUC than SHR (p<0.05)(Table 3) 
but MR displaying no statistically significant differences (p=0.08). 
Comparison within strain 
No chronic H2S treatment differences were observed in the acute H2S relaxation 
curves with point-by-point analysis in either SHR or WKY groups (Figure 10). There 
were also no differences in maximal relaxation or AUC from the experiments (Table 3). 
 
Endothelium-Dependent Vasorelaxations-ACh and INDO 
Comparison of SHR and WKY control 
No differences were observed with point-by-point analysis (Figure 11). AUC and 




Comparison within strain 
No H2S treatment differences were observed in ACh relaxation curves incubated 
with indomethacin with point-by-point analysis in either SHR or WKY groups (Figure 
12). There were also no differences in maximal relaxation or AUC (Table 3). 
 
Vasocontractions: 
Endothelium-Dependent Vasocontractions-ACh and L-NAME 
Comparison of SHR and WKY control 
Point-by-point analysis revealed that SHR displayed a greater development in 
tension at concentrations 10-6 log M to 10-4 log M than WKY (Figure 13). SHR 
demonstrated a greater AUC than WKY (p<0.0001)(Table 4) as well as higher tension 
development at a maximal dose of ACh (p<0.0001)(Table 4). 
Comparison within strain 
No H2S treatment differences were observed in ACh tension development 
experiments incubated with L-NAME with point-by-point analysis in either SHR or 
WKY groups (Figure 14). There were also no differences in maximal contraction or AUC 
between either H2S treatment group and its respective control (Table 4). 
 
Thromboxane-Prostanoid Receptor Sensitivity-U46619 
Comparison of SHR and WKY control 
No statistically significant differences were observed in either point-by point, 
AUC or maximal contraction analysis between strains (Figure 15)(Table 4). 
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Comparison within strain 
There were no statistically significant differences in tension development with 
U46619 with point-by-point analysis (Figure 15). Maximal contractions and AUC 
analysis were not significantly different (Table 4). 
 
Biochemical Assessments: 
6 keto PGF1α Competitive Enzyme Immunoassay – Prostacyclin Production: 
As expected, there was a significant increase in prostacyclin production by the 
SHR CON group compared to the WKY CON group (WKY: 139±23 pg/ml, SHR: 
341±30 pg/ml, p<0.0001). H2S treatment did not affect prostacyclin production in either 
WKY (132±20 pg/ml) or SHR (353±66 pg/ml) (Figure 16). 
 
Western Blotting  
Due to tissue limitations there was not sufficient WKY H2S treatment data to be 
included in the analysis. Therefore, multiple student’s t-tests were performed between 
SHR CON vs. WKY CON as well as SHR CON vs. SHR H2S groups. 
  
eNOS and CSE Protein Expression: 
 Similar to previous reports 11, SHR CON displayed an increase in eNOS protein 
content when compared to the WKY CON (SHR: 2.005±0.27, WKY:1±0.18 both 
arbitrary normalized units, p=0.02)(Figure 17). There was no statistically significant 
difference between the SHR CON and the SHR H2S groups (SHR CON: 2.005±0.27, 
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SHR H2S: 2.610±0.63, both arbitrary normalized units, p=0.31)(Figure 17). There were 
















































Table 1: Animal Characteristics and Hemodynamic Parameters 
 
 WKY SHR 
 Control H2S Control H2S 
Weight (g)  375.1±4 377.1±5 368.5±5 373.2±7 
Left ventricle to 
body weight ratio α 
2.036±0.015 2.068±0.029 2.618±0.062 2.564±0.044 
Heart rate (bpm) α 349±11 344±19 442±6 415±11 
CCA Blood 
Pressure 












































Animal characteristics and hemodynamic parameters. α represents differences between 






















Table 2: Vasomotor Function Viability Measures 
 
 WKY SHR 
Drug Condition Control H2S Control H2S 
KCl pre-constriction  
(g) α 
1.18±0.04 1.17±0.05 1.23±0.02 1.28±0.04 
PE pre-constriction 
(g) 
1.01±0.06 1.00±0.09 1.05±0.05 1.07±0.05 
Vasomotor function viability measures: Maximum contraction to 60mM KCL and 10-6 log 

































Table 3: Vasomotor Assessment Parameters (Vasorelaxation) 
 
  WKY SHR 
Drug Condition  Control H2S Control H2S 
Endothelium 
dependent 
relaxations                 
(ACh) 








































































Vasomotor assessment parameters: Response to a maximal dose (MR) expressed as a 
percent relaxation from PE pre-contraction and area under the curve (AUC) of 
vasorelaxation assessments. α represents differences between strains. Values are mean ± 


















Table 4: Vasomotor Assessment Parameters (Vasocontraction) 
 
  WKY SHR 
Drug Condition  Control H2S Control H2S 
Endothelium 
dependent 
contractions                 
(L-NAME, ACh) 

































Vasomotor assessment parameters: Response to a maximal dose (MC) expressed as a 
percent of KCL contraction and area under the curve (AUC) of vasocontraction 
assessments. α represents differences between strains. Values are mean ± s.e.m.: 
















Figure 6: Endothelium-dependent relaxation to ACh expressed as a percent relaxation 
from PE pre-contraction. WKY CON vs. SHR CON. Values are mean ± s.e.m., n per 






































Figure 7: Endothelium-dependent relaxation to ACh expressed as a percent relaxation 
from PE pre-contraction. WKY (A) and SHR (B). Values are mean ± s.e.m., n per group 
in parenthesis: Significance levels *=p<0.05. 
 
 


























































Figure 8: Endothelium-independent relaxation to SNP expressed as a percent relaxation 
from PE pre-contraction. All groups. Values are mean ± s.e.m., n per groups in 












































Figure 9: Relaxation to H2S expressed as a percent relaxation from PE pre-contraction. 

































Figure 10: Relaxation to H2S expressed as a percent relaxation from PE pre-contraction. 
WKY (A) and SHR (B). Values are mean ± s.e.m., n per groups in parenthesis. 
 
























































Figure 11: Endothelium-dependent relaxation to ACh following incubation with 
indomethacin, expressed as a percent relaxation from PE pre-contraction. WKY CON vs. 








































Figure 12: Endothelium-dependent relaxation to ACh following incubation with 
indomethacin, expressed as a percent relaxation from PE pre-contraction. WKY (A) and 
SHR (B). Values are mean ± s.e.m., n per group in parenthesis. 
 
 
























































Figure 13: Endothelium-dependent contractions of quiescent rings to ACh following 
incubation with L-NAME, expressed as a percent of KCL contraction. WKY CON vs. SHR 








































Figure 14: Endothelium-dependent contractions of quiescent rings to ACh following 
incubation with L-NAME, expressed as a percent of KCL contraction. WKY (A) and SHR 
(B). Values are mean ± s.e.m., n per groups in parenthesis. 
 





















































Figure 15: Endothelium-independent contractions to TP receptor agonist U46619 in 
quiescent rings, expressed as a percent of KCL contraction. All groups. Values are mean 







































                
Figure 16: Prostacyclin production from CCA segments stimulated with ACh 10-4 log M. 
n=9 per group. α represents differences compared to WKY CON. Values are mean ± 










































                      
Figure 17: Protein expression values for eNOS. Values normalized to WKY CON group. 
n=9 for WKY CON, SHR H2S, n=13 for SHR CON. α represents differences compared to 
WKY CON. Non-continuous lanes illustrating quality of blots are included for control 





















































                      
Figure 18: Protein expression values for CSE. Values normalized to WKY CON group. 
n=8-10 per group. Non-continuous lanes illustrating quality of blots are included for 
















































The purpose of this study was to attempt to elucidate the effects that chronic 
sodium hydrosulfide injections have on endothelium-dependent vasomotor functions of 
the CCA, as well as examining changes in associated biochemical parameters and in 
hemodynamic measures in both the adult SHR and WKY animal models. The main 
findings of this study are: 
 
1. Chronic hydrogen sulfide treatment did not lower blood pressure in adult 
spontaneously hypertensive rats. 
2. Chronic hydrogen sulfide treatment improved relaxation to ACh in SHR treated 
with H2S. 
3. Chronic hydrogen sulfide treatment did not decrease endothelium-dependent 
contractions in the carotid artery. 
4. Chronic hydrogen sulfide treatment did not decrease PGI2 produced by the carotid 
artery. 
5. Chronic hydrogen sulfide treatment did not alter protein expression levels of 
eNOS or CSE in SHR. 
 
Animal Characteristics: 
While previous studies conducted by our laboratory have consistently shown that 
SHR have a greater final body weight than the WKY animals 12,19, this study was unable 
to replicate those results. The discrepancy may be due to the fact that many of the WKY 
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animals used in the myography studies were older than planned, and so may have added 
weight due to their age. This is also the first study from our lab to use SHR animals bred 
from our breeding colony, so these animals may differ slightly genetically from the ones 
purchased from Harlan with respect to the body weight differences observed in the past. 
Vasomotor responses and blood pressure, however, were consistent with previous 
measures obtained from our lab, confirming that they are a viable model to be used in this 
study and in the future. H2S treatment did not cause changes in body weight, which is 
consistent with previous reports 43. 
 
Hemodynamics: 
SHR displayed a mean arterial pressure of 185.2±4.9 mmHg compared to 
108.3±3.6 mmHg in the WKY (Table 1). This confirms that the SHR were indeed 
hypertensive, as these mean arterial pressure values are in line with values found in the 
literature 12,60. Previous studies utilizing chronic H2S treatment and SHR have shown that 
following H2S treatment, the blood pressure in the animals is significantly decreased 42,43. 
Contrary to these results, our study demonstrated that after 5 weeks of H2S treatment, no 
change in blood pressure was observed in the SHR. Some differences may arise from the 
different blood pressure measure protocols used. Both Yan et al. 42and Shi et al. 
43performed blood pressure measurements on conscious animals, while the current study 
performed blood pressure measurements on anesthetized animals. One possible 
explanation for these conflicting results is the age difference in the animals used in the 
previous studies and ours. We used animals 14 weeks of age, where the other 
investigations used animals starting at 4 weeks of age. In newborn and 2-week old SHR, 
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vascular resistance is reduced when compared to age-matched WKY 61. Progressing to 4-
6 weeks of age, SHR display still unchanged vascular resistance, albeit with a higher 
cardiac output 62. SHR aged 3-4 weeks display significantly higher blood pressure than 
age matched WKY controls, but while WKY animals reach their adult blood pressure at 
around 10 weeks of age, SHR blood pressure continues to steeply increase until 
approximately 20 weeks of age 63. This leads to the possibility that beginning the chronic 
treatment with H2S at 14 weeks of age might be past the stage at which it can effectively 
decrease blood pressure. Thus, at 4 weeks of age, H2S might be able to slow the 
progression of vascular remodeling and the progressive increase in blood pressure, while 
at 14 weeks, H2S may be unable to reverse the structural changes and increase in blood 
pressure that have already taken hold. Further experimentation needs to be completed to 
systematically examine when the H2S treatment becomes unable to lower blood pressure, 
as well as the mechanisms for this loss of effect. As it stands, the data indicate that 
chronic H2S treatment does not decrease blood pressure in “adult” animals with 
established hypertension. 
The other difference between previous studies and our own was the site of bolus 
injection. While studies in the literature use an intraperitoneal injection, we used a 
subcutaneous injection for animal care reasons. Over the course of a 5-week injection 
protocol, the likelihood of organ puncture or developing a serious infection are decreased 
with subcutaneous injections compared to intraperitoneal injections. A long-term 
subcutaneous injection regimen is also more comfortable for the animal 64. This change in 
location however may have changed how the treatment affected the vasculature. With an 
intraperitoneal injection, the bolus injection would have bathed the mesenteric artery bed 
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with NaHS, possibly allowing for an acute relaxation of the entire mesenteric arterial bed. 
It is unclear from the literature exactly how long this dilation would have lasted, but it 
may have been long enough to play a role in slowing the progression of vascular 
remodeling in the young rats. With the subcutaneous injection, we can assume that there 
would not be this acute dilation of the entire mesenteric arterial bed 64. Instead, there 
would be a large bolus collected under the skin while the NaHS is distributed through the 
bloodsteam. Our confirmatory experiments have shown (Appendix A) that within ten 
minutes of a subcutaneous injection there is an increase in the H2S content in the blood, 
and Bucci et al. 65 recently showed that a subcutaneous injection of 1 µmol/kg of NaHS 
caused a decrease in blood pressure of 20 mmHg in mice that lasted 10-15 minutes, 
demonstrating that a subcutaneous injection does indeed introduce H2S into the 
bloodstream and cause a reduction in blood pressure.  
There is also evidence that this H2S increase might not be beneficial to an adult 
SHR. A recent study showed that in cultured endothelial cells, exposure to different 
concentrations of NaHS caused an increase in cytosolic calcium originating from 
intracellular pools 66. Expanding on this, Kida et al. recently demonstrated that incubation 
of bovine aortic endothelial cells with NaHS resulted in an increase in cytosolic calcium, 
which led to activation of eNOS, which in turn increased the concentration of NO 50. 
While all these processes may be beneficial and aid in relaxation in young SHR, it may 
exacerbate endothelial dysfunction in adult animals. SHR have established endothelial 
dysfunction, with an increase in intracellular calcium thought to be one of the major 
contributors 3. Should this increase in calcium occur in an endothelial cell with 
endothelial dysfunction, the increased calcium could also lead to COX-1 activation, 
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further increasing the amount of ROS and concentration of PGI2. Increasing NO 
production and superoxide production simultaneously could lead to greater 
concentrations of peroxynitrite, furthering damage and reducing NO-bioavailability. 
Further work investigating the role of H2S stimulated increases in intracellular calcium 
concentrations where endothelial dysfunction is present must be performed in order to 
determine whether it exacerbates endothelial dysfunction.  
Evidence has also been presented showing that H2S can stimulate PLA2 
mobilization and subsequent release of arachadonic acid 67. In this study the authors 
demonstrated that low concentrations of H2S constricted the perfused mesenteric bed, and 
that this constriction was due to increased arachadonic acid but was COX- and NOS- 
independent. Again, in a young animal this increase in arachadonic acid may be 
beneficial, but with endothelial dysfunction, the increase in arachadonic acid could elicit 
negative effects through the COX- mediated production of PGI2.  
 
Vasomotor responses: 
 To the best of our knowledge this is the first study to assess the EDRF and EDCF 
signaling mechanisms in a hypertensive model following chronic H2S treatment. SHR 
animals display impaired relaxation to ACh. With PE pre-contraction, vessels from the 
SHR show normal relaxation characteristics to low and moderate concentrations of ACh, 
but at higher concentrations they show a marked recontraction. This recontraction, a 
hallmark of endothelial dysfunction, has been shown to be due to alterations in NO and 
PGI2 signaling pathways 3. The current study confirmed that the SHR had endothelial 
dysfunction, apparent in the development of tension after 10-6 M ACh (Figure 6).  
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 In agreement with our hypothesis, H2S treatment in the SHR slightly improved 
relaxation to ACh with point-by-point analysis of certain concentrations. These 
differences reached significance at 10-5 and 10-4.5 log M (p<0.05) and close to 
significance at 10-5.5 and (p=0.07) (Figure 7). However, the effects were modest 
compared to what was hypothesized based on previous related studies. ACh stimulation 
triggers many cellular signaling cascades in the endothelium, so molecular inhibitors and 
receptor agonists were used to investigate any changes that might have occurred to the 
NO, PGI2 and H2S signaling pathways to account for the increased relaxation observed in 
H2S treated animals.  
NO Signaling Pathway: 
 Through the use of SNP and INDO, an NO donor and COX-1 inhibitor 
respectively, we are able to assess VSM sensitivity to NO, and NO bioavailability in the 
vessel, respectively. Here we demonstrate that with the comparison of SHR and WKY 
control animals, both the SNP and INDO dose-response curves exhibit no differences 
between strains (Figure 8 and 11, respectively). This result is supported in the literature 
where no strain differences are seen in either curve 68,69. In the current study we found that 
there were no changes to the SNP or INDO dose-response curve with chronic H2S 
treatment (Figure 8 and 12, respectively). To the best of our knowledge, this is the first 
study to produce SNP and INDO dose-response curves in SHR that have been treated 
with H2S, so we cannot confirm these results in the literature. Earlier studies have 
reported that the vasodilatory response elicited by H2S does not involve the cGMP/PKG 
pathway 4,70 and that at physiological concentrations, H2S does not stimulate sGC 32. 
Emerging evidence now suggests, however, that H2S may stimulate PKG directly 65, as 
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well as inhibiting phosphodiesterase (PDE) activity 71. Inhibition of PDE leads to 
increases in cGMP, and direct activation of PKG could be another possible mechanism 
for H2S induced vasodilation. Altering both PDE and PKG could lead to those enzymes 
become more sensitive to upstream signals, and may contribute to the increased 
relaxation seen with ACh stimulation. Further work must be completed to assess the 
possible changes to these pathways with chronic H2S treatment. 
Though we attempted to make semi-quantitative assessments of ROS in carotid 
slices using dihydroethidium staining, this attempt was unsuccessful because of 
confounding factors affecting interpretation of the data (Appendix A). Therefore, we can 
only speculate as to the oxidative state of the endothelial cell. If there was no decrease in 
ROS levels due to the age of the animals, then it seems only logical that no increase in 
NO bioavailability would be revealed from incubation with INDO, and therefore no 
change in the INDO dose-response curve with H2S treatment (Figure 12).  
Previous work from our lab has demonstrated that SHR have increased expression 
of eNOS when compared to WKY controls 12, and we were able to confirm this in the 
current study (Figure 17). Interestingly, this higher expression did not yield an increase in 
NO bioavailability (Figure 11). This has been shown in the literature to be due to eNOS 
uncoupling, where ROS decreases the levels of tetrahydrobiopterin, important for 
stabilization of the eNOS dimer, which leads to increased production of ROS and reduces 
NO production 72. Herein we demonstrate that in SHR treated with H2S, there is a small 
but not significant increase in the expression levels of eNOS when compared to SHR 
control (Figure 17). While there is conflicting literature with respect to whether H2S 
increases or decreases the expression of eNOS, there is evidence to suggest that eNOS 
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mRNA and protein expression can be enhanced when exposed to H2S, supporting our 
findings 49. 
H2S Signaling Pathway: 
Using H2S to induce acute relaxation revealed that the SHR controls had a slightly 
attenuated response compared to the WKY control animal (Table 2A). Though no 
specific point-by-point differences were observed (Figure 9), AUC was significantly 
higher in WKY controls, and maximal relaxation to the highest concentration of H2S 
almost reached significance (p=0.08) (Table 2A). These differences suggest that there 
might be alteration in the VSM that negatively affect the SHR vessels in their ability to 
relax to exogenous H2S. There is evidence that the SHR have differences in the 
expression levels of KIR6.1 and SUR2B, two important subunits of the KATP channel 73. 
Considering that KATP channel activation is the mechanism by which H2S induces 
relaxation, this lower expression of the KATP subunits could account for the slight 
decreased in the relaxation effect seen in SHR vessels. It remains to be seen whether 
these strain differences are present with 4-week-old SHR. H2S treatment did not improve 
the relaxation response to exogenously applied H2S (Figure 10). This demonstrates that 
chronic H2S treatment did not alter the sensitivity of the VSM to H2S. This study is the 
first to our knowledge that investigated NaHS relaxation in SHR treated with H2S, so no 
literature is available to support the finding that H2S treatment did not improve VSM 
sensitivity to H2S. Further investigation is needed to determine whether chronic H2S 
treatment has any effect on the expression of KATP channel subunits. 
 CSE protein expression was found to be no different between WKY and SHR 
controls, as well as no different with H2S treatment (Figure 18). Studies using SHR and 
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chronic H2S treatment have shown that with hypertension, there is a decrease in CSE 
mRNA expression when compared to WKY controls, and that mRNA expression returns 
to WKY control values after H2S treatment 42. It is difficult, however, to relate our 
findings to evidence available in the literature due to our examination of protein 
expression, while others examine mRNA expression. It is oftentimes incorrect to assume 
that an increase in gene expression will lead to an equal magnitude increase in protein 
expression, as there are many steps between transcription and translation 74. Thus, 
increases in CSE mRNA with H2S treatment as reported in the literature may not 
necessarily lead to increases in CSE protein content, as suggested by our current results.  
 
PGI2 Signaling Pathway: 
Incubation with the eNOS inhibitor L-NAME was used to assess COX-mediated 
contriction. In agreement with the literature 12, SHR controls displayed a marked 
recontraction in quiescent rings when compared to WKY control animals (Figure 13). 
This confirms that the SHR animals suffered from endothelial dysfunction, and that a 
large part of the SHR vessel recontraction to ACh was due to overactive PGI2 signaling. 
H2S treatment did not reduce endothelium-dependent contractions in SHR (Figure 14). 
Although there is no evidence for the cAMP/PKA pathway contributing to the 
vasorelaxant effect of H2S 4,70, there is evidence that H2S may interact with the pathway 
in some ways. Lim et al. have presented evidence that NaHS (5-100µM) can reverse 
forskolin-stimulated increases in cAMP in cell lines from aortic smooth muscle cells 75. 
Whether this decrease in accumulation was due to AC inhibition or due to PDE 
stimulation was not tested. With adult SHR, this ability for H2S to possibly decrease 
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cAMP may contribute to the decreased efficacy of the H2S treatment, by further 
removing cAMP signaling from an already dysfunctional endothelium. It will be 
important, in the future, to determine the mechanisms in which H2S interacts with the 
cAMP pathway, and whether this interaction changes with age. It will also be important 
to investigate whether these changes work in a negative manner with endothelial 
dysfunction. 
During endothelial dysfunction, PGI2 preferentially stimulates the TP receptor 
causing contraction of the VSM 3. The sensitivity to the TP receptor agonist U46619 was 
not different between SHR and WKY controls, nor was sensitivity decreased with H2S 
treatment (Figure 15). This leads us to believe that H2S treatment does not alter the 
sensitivity of the TP receptor on the VSM. It has been demonstrated in the literature 
18,76that there are no differences in tension development with the use of the selective TP 
receptor agonist U46619, and we were able to replicate these results in the present study.  
As expected, PGI2 production was significantly increased in the SHR compared to 
the WKY control (Figure 16). This increase in PGI2 production in the SHR has been well 
documented and is thought to be one of the main contributors to the EDCF response 
observed in SHR 3. H2S treatment did not decrease the amount of PGI2 produced by the 
SHR (Figure 16). This finding, along with the finding that H2S treatment did not reduce 
the development in tension with SHR vessels incubated with L-NAME, further suggests 
that chronic H2S treatment, in contrast to hypothesis #3, does not affect the EDCF 
pathway, and that any slight alterations in ACh mediated dilation are due to changes in 




 Tissue limitations made performing biochemical assessments difficult. Arteries 
that were used for hemodynamic measure were unable to be used for biochemical 
analysis due to the manipulation they underwent during the isolation and measurement 
procedures leaving only the opposite carotid artery for biochemical assessment. Vessels 
used for myography were unable to be used due to their incubation with different drugs 
and exposure to different pharmalogical agonists. We planned on performing Western 
blots for COX-1, but due to tissue limitations we were unable to perform those 
experiments. There were original plans to perform a H2S production assay where tissue is 
homogenized and analyzed to assess the H2S production levels from CSE, but the 
shortage in tissue did not allow for this experiment to take place.  
 This study was limited by the way in which hemodynamic measures were taken. 
While a pressure catheter surgically inserted into the CCA is a very direct measure of 
blood pressure, the animal must be anesthetized to take the measurements. Thus, there is 
the risk that differing anesthetization levels of the animals may have an effect on blood 
pressure measurements, but we attempted to counteract this by a large number of animals 
for blood pressure measurement. 
 We had originally planned on assessing oxidative stress of vessel segments by 
performing dihydroethidium staining on cross sectional slices of tissue rings taken from 
the carotid artery remaining after the hemodynamic measures were taken. This staining 
proved difficult to perform and quantify, as some sections from the same artery differed 
substantially in the amount of fluorescence that appeared. More detail on the ROS 
experiments and the difficulties encountered can be found in appendix A.  
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Conclusion: 
 This study demonstrates that chronic H2S treatment at 56μmol/kg did not decrease 
blood pressure of the adult SHR, while only slightly improving ACh mediated dilation at 
certain ACh concentrations. While H2S treatment did not improve vascular smooth 
muscle sensitivity to NO or NO bioavailability, the increased relaxation may have been 
due to other mechanisms that were not explored in the current study. H2S treatment 
seems to have no affect on endothelium-dependent contracting factors, as PGI2 mediated 
contractions, TP receptor sensitivity and PGI2 production were unaffected. All previous 
studies that use a chronic bolus injection of NaHS have shown a decrease in blood 
pressure, though interestingly have chosen a very young age for the animals to begin 
treatment. The present study demonstrated that chronic H2S treatment in the adult SHR 
did not lower blood pressure, and did not alter the EDCF signaling pathway. While ACh 
stimulated relaxation was slightly altered, the mechanisms behind it remain unclear. 
 
Future Directions: 
Further experimentation needs to be completed to systematically examine when the H2S 
treatment becomes unable to lower blood pressure, as well as the mechanisms for this 
loss of effect. It would also be important to expand the vasomotor assessment 
investigations to gather a more thorough idea of what changes are happening with H2S 
treatment. This can include a thorough investigation of how H2S interacts with the cAMP 
pathway in a hypertensive model, as well as probing possible alterations to PDE and 
PKG activity. It will also be important to determine whether H2S treatment alters PLA2 
expression and arachadonic acid levels in hypertensive animals. Further investigation is 
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needed to determine whether chronic H2S treatment has any effect on the expression of 
KATP channel subunits as well as investigating the role of H2S stimulated increases in 
intracellular calcium concentrations where endothelial dysfunction is present in order to 

























A segment of the right common carotid artery taken after hemodynamic measures was 
used to assess superoxide production using dihydroethidium fluorescence. Briefly, 
segments were frozen in OCT compound and transverse sections (10µm) were generated 
using a cryostat. Sections were then incubated with 10µmol/l dihydroethidium 
(Molecular Probes) for 30 minutes on a 37° C shaker in a light sealed box. Rings were 
visualized with an Axio Observer Z1 structured-illumination fluorescent microscope 
equipped with standard Red/Green/Blue filters, an AxioCam HRm camera, and 
AxioVision software (Carl Zeiss). Fluorescent images were analyzed using ImageJ 
software 43. 
Difficulties: 
The majority of difficulties came during the analysis of the acquired images. It was 
difficult to obtain consistent staining, even on arterial segments that were on the same 
slide. It is unclear whether the differences seen can be attributed to arterial segments not 
being equally coated with the dye, or whether it was exposure time while under the 
microscope. We had first decided to attempt to quantify fluorescence for multiple 
individual stained nuclei in a given file, however this proved to be technically difficult, 
time consuming, and at times biased. Others had reported quantifying the entire picture, 
and taking multiple pictures to be the average for a single animal, yet with an arterial 
slice there is area in the file that was not part of the artery, skewing the fluorescence 
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analysis. We decided to use a system where a box of set dimensions was placed over a 
section of artery and the fluorescence from that section was quantified. This was then 
repeated for the whole arterial segment, with a final average being the average for that 
arterial ring. Multiple rings were analyzed for a single animal, with the average 
fluorescence of the rings being the final average fluorescence for that animal. Again, this 
was difficult to replicate from file to file, as placing the boxes on the segment still left 
area in the artery that was not analyzed. 
   
Silver/Sulfide Electrode Experiments: 
Methods: 
A small subset (n=8) of female Sprague-Dawley rats were used to confirm that the H2S 
injection being administered subcutaneously was able to increase H2S levels in the blood. 
Animals were injected with sodium pentobarbital (50-65 mg/kg i.p.; Bimeda-MYC, 
Cambridge, ON). The level of anesthetization was monitored through the withdrawl 
reflex from a toe pinch. To ensure proper levels of anesthetization, additional sodium 
pentobarbital was injected until withdrawl reflex was absent. Animals were then given a 
56μmol/kg subcutaneous injection, and blood was collected after 10 minutes. Blood 
collection was taken from the right ventricle using an 18 gauge needle and approximately 
5-6 ml of blood was obtained from each animal. The blood was then separated into three 
2 ml eppendorf tubes, left to clot for 10 minutes, rimmed, centrifuged for 3 minutes at 
8000 rpm, and plasma was collected. Following collection of blood, animals were 
sacrificed by exsanguination. 500 µl of plasma was then mixed with 250 µl deionized 
water and 250 µl sulfide anti-oxidant buffer (SAOB)(0.35g ascorbic acid, 0.67g disodium 
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EDTA in 10 ml of 2M NaOH). The sulfide electrode (Fisher Scientific, Pittsburgh, PA) 
was washed with distilled water, blotted dry and immersed in the sample. The electrode 
potential was recorded using a Fisher Accumet AB15 pH meter (Fisher Scientific, 
Pittsburgh, PA) when the reading stabilized. A standard curve was created using 
increasing concentrations of sodium sulfide to calculate the concentration of H2S in the 
samples, as well as to ensure that readings taken on subsequent days could be compared 
77. The average of each standard concentration was used and fit with a semilog line with 
the equation Y = -33.32*log(X) - 663.1. Millivolt readings from the samples were then 
converted to concentrations and corrected using a dilution factor of two.   
Results: 
Standard Curve: 
A sodium sulfide standard curve was prepared daily to allow for comparison of results. 
The standard was made up to 25, 50, 100 and 200 µM concentrations. The plot of 
electrode potential values to H2S concentration is displayed in Figure 19. 
Electrode Values: 
Our results show that after an H2S subcutaneous injection, the H2S concentration in the 
plasma was significantly different when compared to animals that had been given an 
equal volume of saline (CON: 2.31±0.55 µM, H2S: 13.24±4.40 µM, p<0.05)(Figure 20). 












                    







                         
Figure 20: H2S Concentration in µM. n=4 for each group. α represents differences with 



















































1. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation 
of arterial smooth muscle by acetylcholine. Nature 1980;288(5789):373-376. 
 
2. Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endothelium-derived 
relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad 
Sci U S A 1987;84(24):9265-9269. 
 
3. Félétou M, Vanhoutte PM. Endothelial dysfunction: a multifaceted disorder (The 
Wiggers Award Lecture). Am J Physiol Heart Circ Physiol 2006;291(3):H985-1002. 
 
4. Zhao W, Wang R. H(2)S-induced vasorelaxation and underlying cellular and 
molecular mechanisms. Am J Physiol Heart Circ Physiol 2002;283(2):H474-H480. 
 
5. Rush JWE, Denniss SG, Graham DA. Vascular nitric oxide and oxidative stress: 
determinants of endothelial adaptations to cardiovascular disease and to physical activity. 
Can J Appl Physiol 2005;30(4):442-474. 
 
6. Omar HA, Cherry PD, Mortelliti MP, Burke-Wolin T, Wolin MS. Inhibition of 
coronary artery superoxide dismutase attenuates endothelium-dependent and -
independent nitrovasodilator relaxation. Circ Res 1991;69(3):601-608. 
 
7. Carneado J, Alvarez de Sotomayor M, Perez-Guerrero C, Jimenez L, Herrera MD, 
Pamies E, Martin-Sanz MDV, Stiefel P, Miranda M, Bravo L, Marhuenda E. Simvastatin 
improves endothelial function in spontaneously hypertensive rats through a superoxide 
dismutase mediated antioxidant effect. J Hypertens 2002;20(3):429-437. 
 
8. Gryglewski RJ, Palmer RM, Moncada S. Superoxide anion is involved in the 
breakdown of endothelium-derived vascular relaxing factor. Nature 1986;320(6061):454-
456. 
 
9. Lüscher TF, Vanhoutte PM. Endothelium-dependent contractions to acetylcholine in 
the aorta of the spontaneously hypertensive rat. Hypertension 1986;8(4):344-348. 
 
10. Tang EHC, Vanhoutte PM. Prostanoids and reactive oxygen species: team players in 
endothelium-dependent contractions. Pharmacol Ther 2009;122(2):140-149. 
 66 
 
11. Vanhoutte PM, Tang EHC. Endothelium-dependent contractions: when a good guy 
turns bad! J Physiol 2008;586(Pt 22):5295-5304. 
 
12. Denniss SG, Rush JWE. Impaired hemodynamics and endothelial vasomotor function 
via endoperoxide-mediated vasoconstriction in the carotid artery of spontaneously 
hypertensive rats. Am J Physiol Heart Circ Physiol 2009;296(4):H1038-H1047. 
 
13. Numaguchi Y, Harada M, Osanai H, Hayashi K, Toki Y, Okumura K, Ito T, 
Hayakawa T. Altered gene expression of prostacyclin synthase and prostacyclin receptor 
in the thoracic aorta of spontaneously hypertensive rats. Cardiovasc Res 1999;41(3):682-
688. 
 
14. Huang JS, Ramamurthy SK, Lin X, Le Breton GC. Cell signalling through 
thromboxane A2 receptors. Cell Signal 2004;16(5):521-533. 
 
15. Levy JV. Prostacyclin-induced contraction of isolated aortic strips from normal and 
spontaneously hypertensive rats (SHR). Prostaglandins 1980;19(4):517-525. 
 
16. Williams SP, Dorn GW, Rapoport RM. Prostaglandin I2 mediates contraction and 
relaxation of vascular smooth muscle. Am J Physiol 1994;267(2 Pt 2):H796-H803. 
 
17. Tang EHC, Vanhoutte PM. Gene expression changes of prostanoid synthases in 
endothelial cells and prostanoid receptors in vascular smooth muscle cells caused by 
aging and hypertension. Physiol Genomics 2008;32(3):409-418. 
 
18. Ge T, Hughes H, Junquero DC, Wu KK, Vanhoutte PM, Boulanger CM. 
Endothelium-dependent contractions are associated with both augmented expression of 
prostaglandin H synthase-1 and hypersensitivity to prostaglandin H2 in the SHR aorta. 
Circ Res 1995;76(6):1003-1010. 
 
19. Denniss SG, Jeffery AJ, Rush JWE. RhoA-Rho kinase signaling mediates 
endothelium- and endoperoxide-dependent contractile activities characteristic of 
hypertensive vascular dysfunction. Am J Physiol Heart Circ Physiol 2010;298(5):H1391-
H1405. 
 




21. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of 
oxidant stress. Circ Res 2000;87(10):840-844. 
 
22. Kerr S, Brosnan MJ, McIntyre M, Reid JL, Dominiczak AF, Hamilton CA. 
Superoxide anion production is increased in a model of genetic hypertension: role of the 
endothelium. Hypertension 1999;33(6):1353-1358. 
 
23. Simão S, Gomes P, Pinto V, Silva E, Amaral JS, Igreja B, Afonso J, Serrão MP, 
Pinho MJ, Soares-da-Silva P. Age-related changes in renal expression of oxidant and 
antioxidant enzymes and oxidative stress markers in male SHR and WKY rats. Exp 
Gerontol 2011;46(6):468-474. 
 
24. Price DT, Vita JA, Keaney JF. Redox control of vascular nitric oxide bioavailability. 
Antioxid Redox Signal 2000;2(4):919-935. 
 
25. Rubanyi GM, Vanhoutte PM. Superoxide anions and hyperoxia inactivate 
endothelium-derived relaxing factor. Am J Physiol 1986;250(5 Pt 2):H822-H827. 
 
26. Münzel T, Daiber A, Ullrich V, Mülsch A. Vascular consequences of endothelial 
nitric oxide synthase uncoupling for the activity and expression of the soluble guanylyl 
cyclase and the cGMP-dependent protein kinase. Arterioscler Thromb Vasc Biol 
2005;25(8):1551-1557. 
 
27. Kusama N, Kajikuri J, Yamamoto T, Watanabe Y, Suzuki Y, Katsuya H, Itoh T. 
Reduced hyperpolarization in endothelial cells of rabbit aortic valve following chronic 
nitroglycerine administration. Br J Pharmacol 2005;146(4):487-497. 
 
28. Zou MH, Cohen R, Ullrich V. Peroxynitrite and vascular endothelial dysfunction in 
diabetes mellitus. Endothelium 2004;11(2):89-97. 
 
29. Elsey DJ, Fowkes RC, Baxter GF. Regulation of cardiovascular cell function by 
hydrogen sulfide (H(2)S). Cell Biochem Funct 2010;28(2):95-106. 
 
30. Wang R. Two’s company, three’sa crowd: can H2S be the third endogenous gaseous 
transmitter? the FASEB Journal 2002;16(13):1792-1792. 
 
31. Warenycia MW, Goodwin LR, Benishin CG, Reiffenstein RJ, Francom DM, Taylor 
 68 
JD, Dieken FP. Acute hydrogen sulfide poisoning. Demonstration of selective uptake of 
sulfide by the brainstem by measurement of brain sulfide levels. Biochem Pharmacol 
1989;38(6):973-981. 
 
32. Abe K, Kimura H. The possible role of hydrogen sulfide as an endogenous 
neuromodulator. J Neurosci 1996;16(3):1066-1071. 
 
33. Yang G, Wu L, Jiang B, Yang W, Qi J, Cao K, Meng Q, Mustafa AK, Mu W, Zhang 
S, Snyder SH, Wang R. H2S as a physiologic vasorelaxant: hypertension in mice with 
deletion of cystathionine gamma-lyase. Science 2008;322(5901):587-590. 
 
34. Verma A, Hirsch DJ, Glatt CE, Ronnett GV, Snyder SH. Carbon monoxide: a 
putative neural messenger. Science 1993;259(5093):381-384. 
 
35. Wang R, Wu L. The chemical modification of KCa channels by carbon monoxide in 
vascular smooth muscle cells. J Biol Chem 1997;272(13):8222-8226. 
 
36. Mustafa AK, Sikka G, Gazi SK, Steppan J, Jung SM, Bhunia AK, Barodka VM, Gazi 
FK, Barrow RK, Wang R, Amzel LM, Berkowitz DE, Snyder SH. Hydrogen sulfide as 
endothelium-derived hyperpolarizing factor sulfhydrates potassium channels. Circ Res 
2011;109(11):1259-1268. 
 
37. Zhao W, Zhang J, Lu Y, Wang R. The vasorelaxant effect of H(2)S as a novel 
endogenous gaseous K(ATP) channel opener. EMBO J 2001;20(21):6008-6016. 
 
38. Cheng Y, Ndisang JF, Tang G, Cao K, Wang R. Hydrogen sulfide-induced relaxation 
of resistance mesenteric artery beds of rats. Am J Physiol Heart Circ Physiol 
2004;287(5):H2316-H2323. 
 
39. Zhong G, Chen F, Cheng Y, Tang C, Du J. The role of hydrogen sulfide generation in 
the pathogenesis of hypertension in rats induced by inhibition of nitric oxide synthase. J 
Hypertens 2003;21(10):1879-1885. 
 
40. Yanfei W, Lin S, Junbao D, Chaoshu T. Impact of L-arginine on hydrogen 
sulfide/cystathionine-gamma-lyase pathway in rats with high blood flow-induced 
pulmonary hypertension. Biochem Biophys Res Commun 2006;345(2):851-857. 
 
41. Chunyu Z, Junbao D, Dingfang B, Hui Y, Xiuying T, Chaoshu T. The regulatory 
 69 
effect of hydrogen sulfide on hypoxic pulmonary hypertension in rats. Biochem Biophys 
Res Commun 2003;302(4):810-816. 
 
42. Yan H, Du J, Tang C. The possible role of hydrogen sulfide on the pathogenesis of 
spontaneous hypertension in rats. Biochem Biophys Res Commun 2004;313(1):22-27. 
 
43. Shi YX, Chen Y, Zhu YZ, Huang GY, Moore PK, Huang SH, Yao T, Zhu YC. 
Chronic sodium hydrosulfide treatment decreases medial thickening of intramyocardial 
coronary arterioles, interstitial fibrosis, and ROS production in spontaneously 
hypertensive rats. Am J Physiol Heart Circ Physiol 2007;293(4):H2093-H2100. 
 
44. Rumiko H, Norio M, Hideo K. The Possible Role of Hydrogen Sulfide as an 
Endogenous Smooth Muscle Relaxant in Synergy with Nitric Oxide. Biochem Biophys 
Res Commun 1997;237(3):527-531. 
 
45. Zhao W, Ndisang JF, Wang R. Modulation of endogenous production of H2S in rat 
tissues. Can J Physiol Pharmacol 2003;81(9):848-853. 
 
46. Geng B, Cui Y, Zhao J, Yu F, Zhu Y, Xu G, Zhang Z, Tang C, Du J. Hydrogen 
sulfide downregulates the aortic L-arginine/nitric oxide pathway in rats. Am J Physiol 
Regul Integr Comp Physiol 2007;293(4):R1608-R1618. 
 
47. Kubo S, Doe I, Kurokawa Y, Nishikawa H, Kawabata A. Direct inhibition of 
endothelial nitric oxide synthase by hydrogen sulfide: contribution to dual modulation of 
vascular tension. Toxicology 2007;232(1-2):138-146. 
 
48. Kubo S, Kurokawa Y, Doe I, Masuko T, Sekiguchi F, Kawabata A. Hydrogen sulfide 
inhibits activity of three isoforms of recombinant nitric oxide synthase. Toxicology 
2007;241(1-2):92-97. 
 
49. Meng J, Ganesan Adaikan P, Srilatha B. Hydrogen sulfide promotes nitric oxide 
production in corpus cavernosum by enhancing expression of endothelial nitric oxide 
synthase. Int J Impot Res 2012; 
 
50. Kida M, Sugiyama T, Yoshimoto T, Ogawa Y. Hydrogen sulfide increases nitric 
oxide production with calcium-dependent activation of endothelial nitric oxide synthase 
in endothelial cells. Eur J Pharm Sci 2013;48(1-2):211-215. 
 
 70 
51. Claudia C. B, John P. B, Karen E. P, Chris P. Modulation of Ca2+ signalling in 
human vascular endothelial cells by hydrogen sulfide. Atherosclerosis 2010;209(2):374-
380. 
 
52. Geng B, Chang L, Pan C, Qi Y, Zhao J, Pang Y, Du J, Tang C. Endogenous hydrogen 
sulfide regulation of myocardial injury induced by isoproterenol. Biochem Biophys Res 
Commun 2004;318(3):756-763. 
 
53. Chang L, Geng B, Yu F, Zhao J, Jiang H, Du J, Tang C. Hydrogen sulfide inhibits 
myocardial injury induced by homocysteine in rats. Amino Acids 2008;34(4):573-585. 
 
54. Muzaffar S, Shukla N, Bond M, Newby AC, Angelini GD, Sparatore A, Del Soldato 
P, Jeremy JY. Exogenous hydrogen sulfide inhibits superoxide formation, NOX-1 
expression and Rac1 activity in human vascular smooth muscle cells. J Vasc Res 
2008;45(6):521-528. 
 
55. Samhan-Arias AK, Garcia-Bereguiain MA, Gutierrez-Merino C. Hydrogen sulfide is 
a reversible inhibitor of the NADH oxidase activity of synaptic plasma membranes. 
Biochem Biophys Res Commun 2009;388(4):718-722. 
 
56. Whiteman M, Armstrong JS, Chu SH, Jia-Ling S, Wong BS, Cheung NS, Halliwell B, 
Moore PK. The novel neuromodulator hydrogen sulfide: an endogenous peroxynitrite 
'scavenger'? J Neurochem 2004;90(3):765-768. 
 
57. Kimura Y, Kimura H. Hydrogen sulfide protects neurons from oxidative stress. 
FASEB journal : official publication of the Federation of American Societies for 
Experimental Biology 2004;18(10):1165-1167. 
 
58. Wei HL, Zhang CY, Jin HF, Tang CS, Du JB. Hydrogen sulfide regulates lung tissue-
oxidized glutathione and total antioxidant capacity in hypoxic pulmonary hypertensive 
rats. Acta Pharmacol Sin 2008;29(6):670-679. 
 
59. Kandil S, Brennan L, McBean GJ. Glutathione depletion causes a JNK and 
p38MAPK-mediated increase in expression of cystathionine-gamma-lyase and 
upregulation of the transsulfuration pathway in C6 glioma cells. Neurochem Int 
2010;56(4):611-619. 
 
60. Rush JWE, Quadrilatero J, Levy AS, Ford RJ. Chronic resveratrol enhances 
endothelium-dependent relaxation but does not alter eNOS levels in aorta of 
 71 
spontaneously hypertensive rats. Exp Biol Med (Maywood) 2007;232(6):814-822. 
 
61. Karr-Dullien V, Bloomquist EI, Beringer T, El-Bermani AW. Flow-pressure 
relationships in newborn and infant spontaneously hypertensive rats. Blood Vessels 
1981;18(6):245-252. 
 
62. Prewitt RL, Dowell RF. Structural vascular adaptations during the developmental 
stages of hypertension in the spontaneously hypertensive rat. Bibl Anat 1979;(18):169-
173. 
 
63. Zicha J, Kunes J. Ontogenetic aspects of hypertension development: analysis in the 
rat. Physiol Rev 1999;79(4):1227-1282. 
 
64. Hedrich HJ. The Laboratory Mouse. 2012. 868 p. 
 
65. Bucci M, Papapetropoulos A, Vellecco V, Zhou Z, Zaid A, Giannogonas P, 
Cantalupo A, Dhayade S, Karalis KP, Wang R, Feil R, Cirino G. cGMP-Dependent 
Protein Kinase Contributes to Hydrogen Sulfide-Stimulated Vasorelaxation. PloS one 
2012;7(12):e53319. 
 
66. Bauer CC, Boyle JP, Porter KE, Peers C. Modulation of Ca(2+) signalling in human 
vascular endothelial cells by hydrogen sulfide. Atherosclerosis 2010;209(2):374-380. 
 
67. d'Emmanuele di Villa Bianca R, Sorrentino R, Coletta C, Mitidieri E, Rossi A, 
Vellecco V, Pinto A, Cirino G, Sorrentino R. Hydrogen sulfide-induced dual vascular 
effect involves arachidonic acid cascade in rat mesenteric arterial bed. J Pharmacol Exp 
Ther 2011;337(1):59-64. 
 
68. Sunano S, Watanabe H, Tanaka S, Sekiguchi F, Shimamura K. Endothelium-derived 
relaxing, contracting and hyperpolarizing factors of mesenteric arteries of hypertensive 
and normotensive rats. Br J Pharmacol 1999;126(3):709-716. 
 
69. Li F, Joshua IG. Decreased arteriolar endothelium-derived relaxing factor production 
during the development of genetic hypertension. Clin Exp Hypertens 1993;15(3):511-526. 
 
70. Kiss L, Deitch EA, Szabó C. Hydrogen sulfide decreases adenosine triphosphate 




71. Bucci M, Papapetropoulos A, Vellecco V, Zhou Z, Pyriochou A, Roussos C, 
Roviezzo F, Brancaleone V, Cirino G. Hydrogen sulfide is an endogenous inhibitor of 
phosphodiesterase activity. Arterioscler Thromb Vasc Biol 2010;30(10):1998-2004. 
 
72. Bhatt SR, Lokhandwala MF, Banday AA. Resveratrol prevents endothelial nitric 
oxide synthase uncoupling and attenuates development of hypertension in spontaneously 
hypertensive rats. Eur J Pharmacol 2011;667(1-3):258-264. 
 
73. Blanco-Rivero J, Gamallo C, Aras-López R, Cobeño L, Cogolludo A, Pérez-Vizcaino 
F, Ferrer M, Balfagon G. Decreased expression of aortic KIR6.1 and SUR2B in 
hypertension does not correlate with changes in the functional role of K(ATP) channels. 
Eur J Pharmacol 2008;587(1-3):204-208. 
 
74. Greenbaum D, Colangelo C, Williams K, Gerstein M. Comparing protein abundance 
and mRNA expression levels on a genomic scale. Genome Biol 2003;4(9):117. 
 
75. Lim JJ, Liu YH, Khin ESW, Bian JS. Vasoconstrictive effect of hydrogen sulfide 
involves downregulation of cAMP in vascular smooth muscle cells. Am J Physiol Cell 
Physiol 2008;295(5):C1261-C1270. 
 
76. Chan CKY, Mak JC, Man RYK, Vanhoutte PM. Rho kinase inhibitors prevent 
endothelium-dependent contractions in the rat aorta. J Pharmacol Exp Ther 
2009;329(2):820-826. 
 
77. Meng QH, Yang G, Yang W, Jiang B, Wu L, Wang R. Protective Effect of Hydrogen 
Sulfide on Balloon Injury-Induced Neointima Hyperplasia in Rat Carotid Arteries. Am J 
Pathol 2007;170(4):1406-1414. 
 
 
